<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SIAL</title>
	<atom:link href="http://www.stockbloghub.com/tag/sial/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Added in Russell 1000 and 3000</title>
		<link>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895</link>
		<comments>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:57:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77895</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) announced that it has been included in the Russell 1000 and the Russell 3000 Indices. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe and includes approximately 1,000 of the largest securities based on a combination of their market cap and current index. On the other hand, the Russell 3000 index evaluates the performance of the 3,000 largest U.S. companies by market capitalization. The constituents of the indices will remain in place for a year. Qiagen is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.  Over the years, the company  has developed a comprehensive portfolio of more than 500 proprietary, consumable products, and automated solutions for sample collection.  The company specializes in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Hopeful of Ipsogen Takeover</title>
		<link>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626</link>
		<comments>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626#comments</comments>
		<pubDate>Mon, 20 Jun 2011 00:33:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76626</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) entered into an agreement to acquire 47% stake in France based Ipsogen at €12.90 per share. Thereafter, Qiagen wishes to make a public offer to fully acquire the company. With Ipsogen, Qiagen would have access to a wide portfolio of biomarkers targeted to patients suffering from with blood cancer. Ipsogen recorded 24% sales growth in 2010 to €8.4 million (approximately $11 million). The total value on fully acquiring Ipsogen would stand at €70 million (fully diluted) or $101 million (at exchange rate of €1.00 = $1.44). The whole transaction (including the public offer) is expected to be completed by the third quarter of 2011. Qiagen would fund this acquisition using its existing cash balance. The transaction, on an adjusted basis, would be slightly dilutive to adjusted EPS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIAL) Sigma-Aldrich Modifying Silkworms for Spider Silk</title>
		<link>http://www.stockbloghub.com/2011/04/13/sial-sigma-aldrich-modifying-silkworms-for-spider-silk/71484</link>
		<comments>http://www.stockbloghub.com/2011/04/13/sial-sigma-aldrich-modifying-silkworms-for-spider-silk/71484#comments</comments>
		<pubDate>Thu, 14 Apr 2011 02:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Specialty Chemicals]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71484</guid>
		<description><![CDATA[Biotechnology giant Sigma-Aldrich Corporation’s (SIAL) biological products and services research unit, Sigma Life Science, has entered into a licensing agreement with Kraig Biocraft Laboratories Inc. to develop genetically modified silkworms for the production of spider silk. Per the agreement, the companies will use Sigma&#8217;s proprietary CompoZr Zinc Finger Nuclease (ZFN) technology. This co-operation will ensure speedy and bulk production; in addition, Kraig has also been granted a license by Sigma to use the technology in the textile and biomedical markets. According to the agreement, Kraig will get the exclusive right to use Sigma’s ZFN technology to target the insertion of spider silk genes into the silkworm genome while removing endogenous silkworm silk genes.  This process will eventually lead to producing silkworms that will be capable of spinning pure spider silk ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/sial-sigma-aldrich-modifying-silkworms-for-spider-silk/71484/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIAL) Sigma-Aldrich Group is on a Growth Path</title>
		<link>http://www.stockbloghub.com/2010/03/27/sial-sigma-aldrich-group-is-on-a-growth-path/31558</link>
		<comments>http://www.stockbloghub.com/2010/03/27/sial-sigma-aldrich-group-is-on-a-growth-path/31558#comments</comments>
		<pubDate>Sat, 27 Mar 2010 21:37:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Specialty Chemicals]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31558</guid>
		<description><![CDATA[Sigma-Aldrich Group (SIAL) has announced plans to invest $2 million in expanding the production of trimethylgallium (TMG) at its Bromborough, Wirral, UK manufacturing plant. The investment is expected to establish Sigma as a leading global supplier of TMG, which has a growing demand in the production of high brightness light-emitting diode used in backlighting in flat panel television sets and for energy efficient lighting under its SAFC Hitech business segment. The TMG plant expansion is a part of the annual business plan for 2010, which Sigma-Aldrich has recently. The business plan deals with the company’s long-term financial objectives. For the next five years, the company is anticipating an average growth of 7% to 8% in revenues (versus its prior guidance of 7%). The growth in revenues reflect expectations for 3% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/sial-sigma-aldrich-group-is-on-a-growth-path/31558/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIAL) Sigma-Aldrich Group Inches Ahead of Expectations</title>
		<link>http://www.stockbloghub.com/2010/02/12/sial-sigma-aldrich-group-inches-ahead-of-expectations/27756</link>
		<comments>http://www.stockbloghub.com/2010/02/12/sial-sigma-aldrich-group-inches-ahead-of-expectations/27756#comments</comments>
		<pubDate>Fri, 12 Feb 2010 17:37:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Specialty Chemicals]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27756</guid>
		<description><![CDATA[Sigma-Aldrich Group (SIAL) reported fourth quarter earnings of 75 cents, compared to the Zacks Consensus Estimate of 73 cents and prior-year EPS of 68 cents. Quarterly sales of $572.5 million were up 12.3% from the fourth quarter of 2008. Excluding currency translation impact, the company posted organic growth of 5.6%. Organic sales for the Research business grew 3.1%, while organic sales for SAFC (Sigma Aldrich Fine Chemicals) increased by 11.6%. SAFC’s strong organic growth was driven by sales of H1N1 vaccine adjuvants to pharma companies and shipments of industrial media and other previously booked orders. SAFC&#8217;s booked orders for future delivery as of December 31, 2009 were 16% higher from the year-ago period. The operating margin in the reported quarter, excluding restructuring costs was 22.3% compared to 22.5% in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/12/sial-sigma-aldrich-group-inches-ahead-of-expectations/27756/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIAL) Sigma-Aldrich Group Division SAFC Completes Expansion</title>
		<link>http://www.stockbloghub.com/2009/10/16/sial-sigma-aldrich-group-division-safc-completes-expansion/17719</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sial-sigma-aldrich-group-division-safc-completes-expansion/17719#comments</comments>
		<pubDate>Sat, 17 Oct 2009 01:04:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Specialty Chemicals]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17719</guid>
		<description><![CDATA[The Pharma division of SAFC, a member of the leading Life Science and High Technology company, Sigma-Aldrich Group (SIAL) has completed the expansion of its Carlsbad, California facility. The facility conducts contract-manufacturing services for SAFC’s late phase and commercial clients. The $12 million expansion project included the addition of two fully segregated viral product-manufacturing suites built to employ the latest in disposable bioreactor technologies. This is aimed to expand SAFC Pharma&#8217;s biologics, viral vaccines and gene therapy manufacturing to commercial quantities. SAFC Pharma&#8217;s Carlsbad site specializes in the process development and manufacturing of viral vaccines and viral therapeutics ? including a full menu of support services ? from preclinical process and analytical development to final fill/finish and commercial bulk drug supplies. The new expansion, designed for multi-lot campaigns Incorporatedludes dedicated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sial-sigma-aldrich-group-division-safc-completes-expansion/17719/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

